Department of Laboratory Medicine, Medical University of Viennagrid.22937.3d, Vienna, Austria.
Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Viennagrid.22937.3d, Vienna, Austria.
Microbiol Spectr. 2022 Feb 23;10(1):e0140221. doi: 10.1128/spectrum.01402-21.
Various commercial anti-Spike SARS-CoV-2 antibody tests are used for studies and in clinical settings after vaccination. An international standard for SARS-CoV-2 antibodies has been established to achieve comparability of such tests, allowing conversions to BAU/mL. This study aimed to investigate the comparability of antibody tests regarding the timing of blood collection after vaccination. For this prospective observational study, antibody levels of 50 participants with homologous AZD1222 vaccination were evaluated at 3 and 11 weeks after the first dose and 3 weeks after the second dose using two commercial anti-Spike binding antibody assays (Roche and Abbott) and a surrogate neutralization assay. The correlation between Roche and Abbott changed significantly depending on the time point studied. Although Abbott provided values three times higher than Roche 3 weeks after the first dose, the values for Roche were twice as high as for Abbott 11 weeks after the first dose and 5 to 6 times higher at 3 weeks after the second dose. The comparability of quantitative anti-Spike SARS-CoV-2 antibody tests was highly dependent on the timing of blood collection after vaccination. Therefore, standardization of the timing of blood collection might be necessary for the comparability of different quantitative SARS-COV-2 antibody assays. This work showed that the comparability of apparently standardized SARS-CoV-2 antibody assays (Roche, Abbott; both given in BAU/mL) after vaccination depends on the time of blood withdrawal. Initially (3 weeks after the first dose AZD1222), there were 3 times higher values in the Abbott assay, but this relationship inversed before boosting (11 weeks after the first dose) with Roche 2 times greater than Abbott. After the booster, Roche quantified ca. 5 times higher levels than Abbott. This must be considered by clinicians when interpreting SARS-CoV-2 antibody levels.
各种商业的 SARS-CoV-2 刺突蛋白抗体检测在接种疫苗后用于研究和临床环境。已经建立了 SARS-CoV-2 抗体的国际标准，以实现这些检测的可比性，允许转换为 BAU/mL。本研究旨在研究接种疫苗后采血时间对抗体检测的可比性。在这项前瞻性观察研究中，使用两种商业的抗刺突结合抗体检测（罗氏和雅培）和替代中和检测，评估了 50 名接受同源 AZD1222 疫苗接种者在第一剂后 3 周和 11 周以及第二剂后 3 周的抗体水平。罗氏和雅培之间的相关性随着研究时间点的不同而显著变化。尽管雅培在第一剂后 3 周提供的数值比罗氏高 3 倍，但罗氏在第一剂后 11 周的数值是雅培的两倍，在第二剂后 3 周的数值是雅培的 5 到 6 倍。定量抗 SARS-CoV-2 刺突蛋白抗体检测的可比性高度依赖于接种疫苗后采血时间。因此，为了不同定量 SARS-COV-2 抗体检测的可比性，可能需要标准化采血时间。这项工作表明，在接种疫苗后，明显标准化的 SARS-CoV-2 抗体检测（罗氏、雅培；均以 BAU/mL 给出）的可比性取决于采血时间。最初（第一剂 AZD1222 后 3 周），雅培检测的数值高 3 倍，但在加强免疫前（第一剂后 11 周），罗氏的数值增加了两倍，比雅培高。在加强免疫后，罗氏定量的水平比雅培高约 5 倍。临床医生在解释 SARS-CoV-2 抗体水平时必须考虑到这一点。
